Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.67) by $0.25, Briefing.com reports. During the same quarter last year, the business posted ($0.62) EPS.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 3.42% during trading on Thursday, reaching $48.81. 1,626,765 shares of the company traded hands. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $57.38. The firm’s 50-day moving average is $46.68 and its 200-day moving average is $34.90. The stock’s market capitalization is $1.10 billion.
Institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC boosted its position in shares of Esperion Therapeutics by 56.7% in the fourth quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 12,122 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares in the last quarter. Nationwide Fund Advisors boosted its position in shares of Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock valued at $1,387,000 after buying an additional 921 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Esperion Therapeutics during the first quarter valued at approximately $961,000. Finally, Wells Fargo & Company MN boosted its position in shares of Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,282 shares in the last quarter. 85.20% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics, Inc. (NASDAQ:ESPR) Announces Earnings Results, Misses Estimates By $0.25 EPS” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://stocknewstimes.com/2017/08/10/esperion-therapeutics-inc-nasdaqespr-announces-earnings-results-misses-estimates-by-0-25-eps.html.
A number of research analysts recently commented on ESPR shares. Zacks Investment Research lowered shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, May 1st. ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, June 22nd. Jefferies Group LLC started coverage on shares of Esperion Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $55.00 price target on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $60.00 price target (up previously from $45.00) on shares of Esperion Therapeutics in a research note on Monday, June 26th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $41.16.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
